The Food and Drug Administration has approved a new generic version of mifepristone, the abortion pill used in combination with misoprostol to end early pregnancies.

The approval, granted to Evita Solutions, comes even as the Department of Health and Human Services continues its review of the drug’s safety.

Pro-life leaders condemned the move, warning that the FDA has expanded access without addressing longstanding concerns about the risks to women and unborn children. Sen. Josh Hawley (R–Mo.) said he has “lost confidence in the leadership at FDA,” while Susan B. Anthony Pro-Life America president Marjorie Dannenfelser called the decision “reckless” and “unconscionable.”

MCFL president, Myrna Maloney Flynn responded: "Abortion champions do not understand that women deserve long-term support and solutions that honor their dignity, not insensitive and dangerous short-term fixes, however well-intentioned they might be. While we are disappointed to know that yet another means for ending innocent human life has been introduced, we're confident that, after its scheduled review of mifepristone, the FDA will reverse course and protect both mothers and their unborn children."

Despite claims from abortion advocates about safety, the reality is that chemical abortion carries serious risks, including hemorrhage, infection, and complications that can send women to emergency rooms. The approval of another generic pill signals a troubling expansion of the abortion industry at a time when pro-life advocates continue to push for stronger protections for mothers and their children.

Read more here.